Despite the fact that in some patients with high-level expression of programmed cell death ligand 1 (PD-L1) in the tumor, there is a greater effectiveness of immunotherapeutic drugs, it does not allow for predicting the presence or absence of a clinical response to treatment. The gene discussed is CD274; the disease is neoplasm.